Welcome to our dedicated page for Leveljump Health news (Ticker: JMPHF), a resource for investors and traders seeking the latest updates and insights on Leveljump Health stock.
LevelJump Healthcare Corp. provides teleradiology and diagnostic imaging services through telehealth solutions for client hospitals and imaging centers and in-person radiology services through its Diagnostic Centres. The company’s updates commonly cover operations serving urgent and emergency care settings, financial reporting matters, and public-company capital actions.
Recurring news themes for JMPHF include non-brokered private placements, common-share issuances, stock option grants under its equity incentive plan, shareholder meeting activity, board composition, cooperation agreements, and other governance matters tied to its status as a publicly traded healthcare services company.
LevelJump Healthcare (JMPHF) has appointed Gus Patel as interim Chief Financial Officer effective September 1, 2026, replacing Robert Landau.
Patel is a finance executive, tax practitioner and licensed public accountant with over 15 years of experience across public and private companies and professional services, including IFRS and ASPE reporting, disclosure, audit and tax oversight, internal controls, treasury, budgeting and transaction advisory.
LevelJump Healthcare (OTC: JMPHF, TSXV: JUMP) reported record Q2 2026 revenue of $5,008,038, up 6.7% from $4,692,007 in Q2 2025. Revenue for the six months ended June 30, 2026 was $9,738,438, a 5.0% increase from $9,273,503 a year earlier.
Quarterly growth was driven by imaging centres, with IHF imaging scan revenue rising to $2,544,018 from $2,348,610 (about 8.3% growth), while teleradiology (radiologist fee) revenue increased to $2,464,020 from $2,343,397 (up 5.1%). EBITDA for Q2 was $185,341, and for the six-month period $270,316. LevelJump reported a net loss of $484,544 for the quarter and $969,961 for the six months. According to LevelJump, the company remains focused on organic growth, expanding services and maximizing revenue opportunities across its CTS, ADC and diagnostic clinic operations.
LevelJump Healthcare (TSXV: JUMP) announced that the Ontario Securities Commission has revoked a cease trade order originally issued against the company on May 6, 2026. LevelJump is now current with its continuous disclosure obligations and is applying to the TSX Venture Exchange for reinstatement of trading in its common shares.
LevelJump Healthcare (JMPHF) reported first quarter 2026 revenues of $4.7 million, up from $4.58 million in Q1 2025, a 2.7% year-over-year increase. The company recorded a net loss of $375,923 and reported EBITDA of $194,468 for Q1 2026.
LevelJump’s 100%-owned subsidiary, Canadian Teleradiology Services, generated EBITDA of $624,311 in the quarter. Management highlighted the use of non-IFRS measures such as adjusted EBITDA for evaluating operating performance and liquidity, while advising investors to consider these alongside IFRS metrics.
LevelJump Healthcare (OTC: JMPHF, TSXV: JUMP) reported 2025 revenues of $19.1 million, up from $17.7 million in 2024, a 7.9% year-over-year increase. Canadian Teleradiology Services, the 100%-owned subsidiary, generated $3.84 million EBITDA in 2025.
For 2025, LevelJump recorded EBITDA of $1,662,510 and a net loss from operations of $815,018. Q4 2025 revenues were $5.1 million with EBITDA of $(105,000). According to LevelJump, the Q4 EBITDA decline mainly reflected legal and ancillary costs tied to a shareholder requisition, which the company does not expect to recur. Management highlights record annual revenue and continued organic demand growth. The release also reiterates that EBITDA and adjusted EBITDA are non-IFRS measures used internally to assess operating performance.
LevelJump Healthcare (OTC: JMPHF) announced a delay in filing its annual financial statements and MD&A for the year ended December 31, 2025. The company says the audit is ongoing and it now expects to file the Required Filings by mid-May 2026. A cease trade order is expected due to the delay. Management and auditors are working to complete the filings and to minimize any prejudice to shareholders.
LevelJump Healthcare (JMPHF) closed a non-brokered private placement effective April 16, 2026, issuing 14,380,000 common shares at C$0.05 per share for gross proceeds of C$719,000.
Securities are subject to a 4-month plus one day hold ending August 17, 2026, and the offering has conditional TSX Venture Exchange acceptance pending final approval. The company paid C$10,150 in finder fees and issued 203,000 non-transferable finder’s warrants exercisable at C$0.05 for two years. Net proceeds will be used for general working capital. Offered shares were placed with arm's length parties and are not registered for U.S. sale.
LevelJump Healthcare (OTC: JMPHF) intends a non-brokered private placement of up to 15,000,000 common shares at $0.05 per share to raise up to $750,000, subject to TSX Venture Exchange approval.
The Offering is expected to close on or around April 16, 2026, carries a four-month-plus-one-day hold, may include insider participation, and aims to fund general working capital. Finder's fees up to 7% cash and 7% in warrants may be payable.
LevelJump Healthcare Corp (OTC: JMPHF) granted 2,250,000 incentive stock options to three directors under its 2022 Equity Incentive Plan. Each option allows purchase of one common share at an exercise price of $0.065 until February 24, 2031. There are no vesting restrictions.
LevelJump Healthcare (OTC Pink: JMPHF) announced a cooperation agreement with shareholder Frank Teti that immediately reconstitutes the board to add independent perspectives. Effective January 20, 2026, Dr. Sheldon Levy, Rob Saltsman, and Sean Aylward were appointed to the board, with Mr. Aylward named chair. In conjunction with these appointments, Gary Prihar, Richard Jagodnik, and Jackie Glazer resigned.
As part of the agreement, Mr. Teti withdrew a prior requisition for a special shareholder meeting and agreed to support the company’s updated director slate at the next annual meeting.